Product Information
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.1828 per EA under NDC 00378300277. Its NADAC has been published 652 times since Nov 28, 2013.
FDA first approved this application on Dec 4, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the candesartan cilexetil and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB
candesartan cilexetil and hydrochlorothiazideStrength
32; 12.5 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378300277
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090704FDA Approved
12/4/2012
TE Code
AB
On Market Since
12/4/2012
Pharmacological Classes
Price Statistics
The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has been published 652 times since Nov 28, 2013, and over the history we have for it it has declined 29.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1828 per EA |
|---|---|
| All-time high | $3.7501 (Jan 11, 2017) |
| All-time low | $0.7888 (Nov 20, 2024) |
| 52-week high | $1.2226 |
| 52-week low | $1.0214 |
| Median price | $1.8792 |
| Average price | $2.0112 |
| Largest weekly change | +63.0% (Jul 20, 2016) |
| Weeks tracked | 652 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
+9.6%
1Y
+3.2%
3Y
-13.1%
5Y
-34.1%
All
-29.5%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $1.1828 per EA (NDC 00378300277), effective May 20, 2026.
How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has declined 29.5%. It has been tracked across 652 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?
Since Nov 28, 2013, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has ranged from a low of $0.7888 (Nov 20, 2024) to a high of $3.7501 (Jan 11, 2017), with a median of $1.8792 per EA.
Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, is $0.9013 per EA — about 24% below CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB.
Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB (NDC 00378300277) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.